40 Top Doctors Just Agreed: Antidepressants Aren’t the First Answer for POTS

By Melissa Chester, BBA · Medically reviewed by Phyllis J. Gee, MD, FACOG
Published October 3, 2026 · Last reviewed October 3, 2026

The first-ever international expert consensus on POTS and dysautonomia just confirmed what patients have said for years — and it’s already reshaping how the condition should be diagnosed and treated.

If you’ve ever been told your racing heart, dizziness, and fatigue were “just anxiety,” you’re not alone — and as of this year, 40 of the world’s leading autonomic specialists officially agree with you. In August 2026, the first multidisciplinary international expert panel ever convened on Postural Orthostatic Tachycardia Syndrome (POTS) published a landmark consensus statement that does something no single study has done before: it tells doctors, in plain terms, what to do differently.

What just changed: the first-ever POTS consensus

Forty specialists from seven countries — cardiologists, neurologists, and autonomic disorder experts, working alongside four patient advocacy organizations — spent months reaching formal agreement on 31 separate statements about how POTS and a newly recognized condition called “non-POTS dysautonomia” should be diagnosed, treated, and discussed. The result, published in The American Journal of Medicine, is the first document of its kind: a true international consensus, not a single institution’s opinion.

Of the 31 statements, 24 reached unanimous, 100% agreement among all 40 experts. The remaining seven still cleared a strong consensus threshold, with agreement ranging from 92.5% to 97.5%. That level of agreement among specialists who don’t always see eye to eye is rare in medicine — and it signals that the recommendations are built on solid ground, not one doctor’s opinion.

Three findings stand out:

• A new diagnosis now has a name. Patients with real autonomic symptoms and functional impairment who don’t meet the strict heart-rate threshold for POTS can now be recognized as having “non-POTS dysautonomia” — a distinction that matters because it means these patients should no longer be dismissed just because a single test came back borderline.
• Antidepressants should not be the default. The panel reached unanimous consensus that psychotherapy or antidepressants should not be used as first-line treatment for POTS or non-POTS dysautonomia, unless a separate mood disorder also requires urgent treatment. This directly contradicts what many patients are told during their diagnostic journey.
• Treatment should start with the basics, immediately. The consensus states plainly that treatment “typically begins with implementation of non-pharmacologic therapies consisting of increased fluid and salt intake, the use of compression garments, and avoidance of triggers” — alongside medication, not instead of it, and without delay.

The panel also pointed to central hypovolemia — essentially, lower-than-normal blood volume — as one of the leading mechanisms behind POTS symptoms. That detail matters, because it’s the actual physiological reason fluid and electrolyte support shows up as a first-line recommendation rather than an afterthought.

Why this matters: the two-year journey most patients already know

This consensus didn’t emerge in a vacuum. A community-based survey of 4,835 diagnosed POTS patients — still the largest ever conducted — found a median diagnostic delay of 24 months, with three out of four patients misdiagnosed first. Seventy-seven percent encountered a doctor who suggested their symptoms were psychiatric. Patients saw an average of seven physicians before getting an answer.

Read alongside the new consensus, that pattern looks less like bad luck and more like a predictable result of a system that reached for antidepressants before it reached for fluids and electrolytes. The new guidance is effectively a course correction, built on exactly the kind of patient experience this survey documented.

What that journey actually costs — one real number

Seven doctor visits take real time and real money. The average U.S. ambulatory visit runs 121 minutes door-to-door, and at 2026’s average hourly wage of $37.81, that time alone is worth about $76 per visit in lost income. Add the average specialist copay — $45, per the 2025 KFF Employer Health Benefits Survey — and seven visits add up to:

Getting the right answer sooner doesn’t just spare patients months of being dismissed. It’s measurably cheaper than the alternative.

The conditions hiding alongside POTS

POTS rarely shows up alone, which is part of why a single specialist, looking at a single symptom, so often misses the full picture. The same 4,835-patient survey found that 83% of respondents had at least one additional diagnosed condition.

Migraine (40%) and irritable bowel syndrome (30%) are the most common, followed by Ehlers-Danlos syndrome (25%) — a connective tissue disorder that, like POTS itself, often goes unrecognized because no single visit is built to catch it.

What happens years later, according to the longest study ever done

A separate 2026 study from the Vanderbilt Autonomic Dysfunction Center and the University of Calgary followed 44 patients with an average follow-up of over 20 years — the longest POTS follow-up ever published. The widely repeated takeaway, “98% still have symptoms,” is accurate but incomplete: the same study found that 46% of those patients reported real improvement over time. Only 2% achieved full resolution, and 25% got worse — but “almost nobody is cured” and “almost half get better” are both true, and most summaries only mention the first one.

The study also found that patients who did not improve were significantly more likely to also have neuropathy, gastroparesis, or an overactive bladder — the same pattern of overlapping conditions described above. Put the new consensus and this outcome data together, and the throughline is consistent: broad, early evaluation beats a slow walk through single-symptom specialists, both for comfort today and for outcomes years from now.

Frequently asked questions

What actually changed with this new consensus?

For the first time, a multidisciplinary international panel agreed on specific, numbered recommendations for diagnosing and treating POTS — including that antidepressants shouldn’t be the default treatment, and that a new category, “non-POTS dysautonomia,” should be recognized for patients who don’t meet the strict heart-rate criteria but still have real autonomic symptoms.

Is “98% still have symptoms after 20 years” misleading?

It’s accurate but incomplete. The same study found 46% of patients reported real improvement, and only 2% achieved full resolution — both numbers come from the same research.

Does this mean IV fluids can cure POTS?

No. The consensus names increased fluid and salt intake as a first-line non-pharmacologic therapy, used alongside medication, not as a cure. It addresses one proposed mechanism — lower blood volume — but POTS has multiple potential causes, and treatment should be individualized with a qualified provider.

What should I do if I suspect I have POTS or non-POTS dysautonomia?

Start with your primary care physician and ask specifically about autonomic testing. If you’re in the Allen, TX area and want to discuss whether fluid and electrolyte support fits into your care, you can also look into InfusaLounge’s POTS Support IV Therapy, built around hydration and electrolyte support for autonomic balance.